Abstract
1019Background: Ductal carcinoma in situ (DCIS) is a heterogeneous disease associated with a spectrum of risk for ipsilateral breast events (IBE). Reducing overtreatment is an important unmet need for DCIS patients. Methods: Patients were from Uppsala University Hospital diagnosed 1986 - 2004, and University of Massachusetts diagnosed 1999 -2008, treated with breast conserving surgery (BCS) with (56%) or without (44%) radiation therapy (RT). Biomarkers (p16/INK4A, Ki-67, COX-2, PgR, HER2, FOXA1, SIAH2 via IHC/ISH) were assessed in FFPE tissue by board-certified pathologists. Pathological and clinical data were collected from medical records. A multi-marker based prognostic was developed on the combined patient sets (n = 600, 8.1 year median follow-up) using multiple cross-validation (patients divided into independent training and testing subsets). Patients with DCIS detected by mammography screening (n = 379) were then stratified into risk categories defined by the multi-marker based prognostic or clinico...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
